comprehensive -WSS

comprehensive

author：explore 2025-09-29 18:15:40 - browse：6652

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

explore

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

Cassava reveals details — and problems — with Alzheimer's study

Paying for Covid pills will soon shift to insurers

The system is set up to fail children with medical complexity

Emergency medicine has repudiated 'excited delirium.' Now what?

CDC recommends rationing of RSV shot due to shortages

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Cancer drug shortages should be causing more outrage

Biden's order seeks to regulate AI risk without stifling innovation

Psychedelics group wrestles with new pharma identity

Readout Newsletter: What happened with Sarepta's Duchenne data

Duchenne breakthrough therapy leaves behind pioneering families

Testing for cancer recurrence creates a new limbo for patients

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Teladoc has a new CEO, but challenges remain the same

In Memoriam: Notable people who died in 2023

ALS patient reclaims some autonomy thanks to wearable 'robot'

hotspot

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: What happened with Sarepta's Duchenne data

Moderna says combo Covid

Medtronic CEO on promising devices for diabetes, hypertension

Diversifying clinical trials isn't enough to close racial gaps: study

Teladoc has a new CEO, but challenges remain the same

explore

knowledge

focus

focus